Eagle Pharmaceuticals (OTCMKTS:EGRX – Get Free Report) will likely be posting its resultson Monday, November 9th. Analysts expect Eagle Pharmaceuticals to post earnings of $0.7330 per share and revenue of $45.03 million for the quarter.
Eagle Pharmaceuticals Stock Performance
OTCMKTS:EGRX opened at $0.95 on Monday. The company’s 50 day moving average is $0.97 and its two-hundred day moving average is $0.55. The company has a market cap of $12.34 million, a PE ratio of 0.81 and a beta of 0.83. Eagle Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $3.94.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc was a specialty pharmaceutical company focused on developing and commercializing injectable and intranasal medicines, with an emphasis on products intended to improve existing therapies through differentiated formulations, dosing approaches, or delivery technologies. The company primarily served hospital, oncology, emergency medicine, and critical-care markets.
Eagle’s marketed products included Ryanodex, an injectable formulation of dantrolene sodium used to treat malignant hyperthermia; Belrapzo, a formulation of bendamustine hydrochloride used in certain blood cancers; and Pemfexy, a ready-to-dilute formulation of pemetrexed used in the treatment of certain lung cancers and mesothelioma.
Read More
- Five stocks we like better than Eagle Pharmaceuticals
- Uranium Prices Are Near Historic Highs—So Why Hasn’t Cameco Followed?
- Royal Caribbean Buys the Beach as Norwegian Fixes the Ship
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
